An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours

Author(s):
Schoffski, P.; Adkins, D.; Blay, J.Y.; Gil, T.; Elias, A.D.; Rutkowski, P.; Pennock, G.K.; Youssoufian, H.; Gelderblom, H.; Willey, R.; Grebennik, D.O.
Published
2013
Publication type
Article / Letter to editor
CixutumumabSoft-tissue sarcomaEwing family of tumoursRhabdomyosarcomaLeiomyosarcomaAdipocytic sarcomaSynovial sarcomaInsulin-like growth factor receptor
Date issued
2013-10-31
Language
English
Is part of
European Journal of Cancer (2013), Vol. 49, no. 15, p. 3219-3228
hdl
1887/102625
doi
10.1016/j.ejca.2013.06.010